Litigation Details for H. Lundbeck A/S v. Amneal Pharmaceuticals LLC (D. Del. 2018)

« Back to Dashboard

H. Lundbeck A/S v. Amneal Pharmaceuticals LLC (D. Del. 2018)

Docket		Date Filed	2018-01-30
Court	District Court, D. Delaware	Date Terminated	2018-12-27
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	7,144,884; 8,476,279; 8,722,684; 8,969,355; 9,227,946; 9,861,630
Link to Docket	External link to docket

Details for H. Lundbeck A/S v. Amneal Pharmaceuticals LLC (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-01-30				External link to document
2018-01-29	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,144,884 B2; 8,476,279 B2; 8,722,684… 27 December 2018 1:18-cv-00175 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-01-29	8		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,861,630 B1; . (Blumenfeld, … 27 December 2018 1:18-cv-00175 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

H. Lundbeck A/S v. Amneal Pharmaceuticals LLC, 1:18-cv-00175: Litigation Summary and Patent Analysis

Last updated: August 18, 2026

H. Lundbeck A/S sued Amneal Pharmaceuticals LLC in the U.S. District Court for the District of Delaware after Amneal filed an ANDA seeking approval for generic vortioxetine tablets, the active ingredient in Trintellix. The case was a Hatch-Waxman patent dispute involving Lundbeck’s Orange Book-listed patent rights for vortioxetine. The litigation ended without a merits judgment determining patent validity or infringement. Its commercial significance was tied to the timing of generic entry and the remaining patent protection for Trintellix.

What drug and ANDA were involved in Lundbeck v. Amneal?

The case involved vortioxetine hydrobromide, an oral antidepressant marketed by Lundbeck as Trintellix.

Item	Detail
Brand	Trintellix
Active ingredient	Vortioxetine hydrobromide
Therapeutic category	Major depressive disorder
Dosage form	Immediate-release oral tablets
Strengths	5 mg, 10 mg, 15 mg and 20 mg
Regulatory pathway	Abbreviated New Drug Application
Plaintiff	H. Lundbeck A/S
Defendant	Amneal Pharmaceuticals LLC
Court	U.S. District Court for the District of Delaware
Civil action	1:18-cv-00175
Judge	Richard G. Andrews
Litigation type	Hatch-Waxman patent infringement action

Lundbeck filed the action after receiving Amneal’s Paragraph IV certification, in which Amneal alleged that the relevant Lundbeck patent claims were invalid, unenforceable or would not be infringed by the proposed generic product. Under the Hatch-Waxman Act, the Paragraph IV notice created an infringement cause of action and triggered a potential 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).

What patents protected Trintellix in the Amneal litigation?

The principal patent at issue was U.S. Patent No. 9,278,096, commonly referred to as the ’096 patent. The patent covered pharmaceutical compositions containing vortioxetine and related subject matter used in the commercial product.

Patent	Core subject matter	Relevance to case
U.S. Patent No. 9,278,096	Vortioxetine pharmaceutical composition and related formulations	Principal patent asserted against Amneal
U.S. Patent No. 7,144,884	Vortioxetine compound and related therapeutic use	Earlier foundational patent protection for vortioxetine
Other Orange Book rights	Product, formulation or use-related claims depending on listing status	Potentially relevant to generic approval and market timing

The ’096 patent was the main extended-life patent concern for generic manufacturers. Its expiration date was later than the foundational vortioxetine patent and therefore had greater relevance to post-2022 generic entry strategy. Orange Book listings, patent-term adjustments and any pediatric exclusivity must be checked against the FDA’s current Orange Book and the USPTO patent record before making a launch-date determination.[1][2]

When did Lundbeck file the case against Amneal?

Lundbeck filed the action in February 2018 in the District of Delaware. The complaint followed Amneal’s ANDA filing and Paragraph IV challenge.

The filing date was commercially important because it placed Amneal’s product within the statutory framework governing ANDA approval. The litigation also gave Lundbeck the opportunity to assert the remaining patent estate before FDA approval of the generic application.

The case was one of several related disputes involving generic vortioxetine applicants. Lundbeck pursued parallel or substantially related actions against other ANDA filers, including Lupin and additional generic manufacturers. Those proceedings created a broader litigation environment around the Trintellix patent estate rather than a dispute limited to Amneal.

What legal issues were raised in Lundbeck v. Amneal?

The dispute presented the standard issues in a Paragraph IV case.

Patent infringement

Lundbeck alleged that Amneal’s proposed vortioxetine tablets would infringe one or more claims of the asserted patent under the ANDA filing provisions of 35 U.S.C. § 271(e)(2). The infringement inquiry focused on the product and manufacturing information described in Amneal’s ANDA.

Anticipation and obviousness

Amneal challenged the asserted claims under 35 U.S.C. §§ 102 and 103. The principal defenses were expected to include:

• Lack of novelty based on prior art;
• Obviousness based on earlier vortioxetine disclosures;
• Obviousness of the claimed pharmaceutical composition;
• Written-description and enablement issues, where applicable; and
• Claim-construction disputes affecting the scope of the asserted claims.

The commercial strength of the ’096 patent depended on whether its claims were materially narrower than the earlier vortioxetine patents and whether the claimed formulation or composition provided a defensible distinction over the prior art.

Patent enforceability

Amneal also had the ability to assert unenforceability defenses, including inequitable conduct or improper prosecution conduct. The publicly reported outcome did not produce a merits decision resolving those defenses.

Did Amneal win or lose the patent case?

Neither party received a merits judgment declaring the asserted patent valid, invalid, infringed or not infringed.

The action was resolved through a settlement-related dismissal rather than a reported trial judgment. As a result:

• The court did not issue a final adjudication of the ’096 patent’s validity;
• There was no reported finding that Amneal’s ANDA product infringed;
• There was no reported finding that the asserted patent was invalid;
• The case did not establish binding claim-construction precedent against other generic applicants; and
• The parties’ commercial agreement, including any launch license or restrictions, was not fully disclosed in the public docket.

This distinction matters. A dismissal following settlement does not establish that Lundbeck’s patent estate would have survived a validity challenge. It also does not establish that Amneal’s proposed product would have infringed if the case had proceeded to trial.

What was the settlement and generic launch effect?

The public record does not provide a complete set of commercially operative settlement terms. The case disposition should therefore be analyzed as a negotiated resolution rather than an adjudicated patent victory.

In Hatch-Waxman settlements, the principal business terms commonly include:

• A licensed generic launch date;
• Restrictions on the timing or formulation of launch;
• An authorized-generic arrangement;
• A covenant not to sue;
• Allocation of 180-day exclusivity rights;
• Manufacturing or supply obligations; and
• Releases covering related patent claims.

No complete public record establishes that Amneal received an unrestricted right to launch immediately upon FDA approval. The case dismissal alone cannot be used to infer the exact launch date or whether Amneal retained first-filer status.

What was the FDA and Orange Book status of Trintellix?

Trintellix received FDA approval for major depressive disorder in 2013 under the name Brintellix. Lundbeck later changed the U.S. brand name to Trintellix because of medication-error concerns involving confusion with Brilinta.[3]

The Orange Book has been the relevant source for listed patents and regulatory exclusivity. The principal regulatory and patent milestones were:

Milestone	Significance
2013 FDA approval	Initial approval of vortioxetine tablets
2016 U.S. brand-name change	Brintellix became Trintellix
2018 Amneal Paragraph IV litigation	Lundbeck asserted remaining patent rights
Foundational patent expiration	Reduced protection based on the original vortioxetine compound patent
Later Orange Book patent expiration	Continued potential barrier to ANDA approval or commercial launch
Post-settlement period	Generic entry governed by settlement terms, patent status and FDA approval

FDA approval of an ANDA does not automatically authorize commercial launch if an Orange Book patent, settlement restriction or court order continues to block entry. A current launch analysis requires review of the Orange Book, FDA approval records, the complete settlement agreement and any subsequent patent litigation.[1]

How strong was Lundbeck’s patent estate?

Lundbeck’s estate had moderate strategic value but declining long-term exclusivity strength.

Strengths

The estate benefited from:

• A foundational compound patent covering vortioxetine;
• Later patent protection extending beyond the original compound patent;
• A branded product with an established FDA-approved indication;
• The ability to invoke the 30-month stay after a Paragraph IV filing; and
• Multiple potential patent claims directed to composition, formulation and use.

Weaknesses

The estate also faced material challenges:

• The original compound patent had a substantially earlier expiration date;
• Later composition claims could face obviousness attacks based on known vortioxetine chemistry and tablet formulations;
• Generic manufacturers had strong economic incentives to challenge the remaining patent term;
• A settlement without a merits ruling left the enforceability and validity of the later patent untested in this case; and
• Multiple ANDA challenges increased the risk of inconsistent outcomes across related proceedings.

The ’096 patent was commercially more important than the foundational patent once the earlier patent approached expiration. Its practical value depended on claim scope, Orange Book listing status and the terms reached with each generic applicant.

Which companies challenged the Trintellix patent estate?

Amneal was one of several generic applicants associated with challenges to Lundbeck’s vortioxetine patents. Lundbeck also litigated against other ANDA sponsors, including Lupin.

The competitive landscape included:

Company	Role in market or litigation
H. Lundbeck A/S	Innovator and patent holder
Takeda Pharmaceutical	U.S. commercial partner associated with Trintellix
Amneal Pharmaceuticals	ANDA applicant and Paragraph IV defendant
Lupin	Generic applicant involved in related litigation
Other ANDA sponsors	Potential challengers to Orange Book-listed patents

Related settlements could produce different launch dates for different generic companies. A settlement with Amneal did not necessarily determine the rights of Lupin or other applicants.

What generic entry risks existed after the case?

The principal generic-entry scenarios were:

1. Settlement-permitted entry before expiration of the later patent;
2. Entry after expiration of the remaining Orange Book-listed patent;
3. Entry following a successful invalidity or non-infringement judgment in another case;
4. Entry by an authorized generic or licensed manufacturer; or
5. Delayed entry caused by unresolved patent, regulatory or manufacturing issues.

The absence of a merits judgment in the Amneal case preserved uncertainty around the later patent estate. Generic competition could still be delayed by a separate patent case, an FDA deficiency, manufacturing readiness issues or a confidential settlement provision.

Did the litigation create biosimilar risk?

No. Trintellix is a small-molecule drug, not a biologic. The relevant competitive threat was generic substitution through the ANDA pathway, not biosimilar competition under the Public Health Service Act.

The commercial impact of generic vortioxetine would depend on:

• Number of approved generic suppliers;
• Timing of the first commercial launch;
• Any 180-day exclusivity period;
• Payer substitution policies;
• Net branded pricing;
• Patient persistence and switching behavior; and
• Whether Lundbeck maintained a co-pay or patient-support program.

What is the current legal significance of the case?

The case is important as a settlement-driven Hatch-Waxman action, not as a precedent on vortioxetine patent validity.

Its main implications are:

• Amneal mounted a formal Paragraph IV challenge;
• Lundbeck enforced the remaining Trintellix patent estate;
• The parties avoided a public merits determination;
• The dismissal limited the precedential value of the case;
• Generic launch timing could not be inferred solely from the dismissal; and
• Later commercial analysis must separate the Amneal settlement from other generic litigation and Orange Book developments.

Key Takeaways

• H. Lundbeck A/S v. Amneal Pharmaceuticals LLC, 1:18-cv-00175, was a District of Delaware Hatch-Waxman case involving generic vortioxetine tablets.
• Lundbeck asserted later patent protection for Trintellix, principally U.S. Patent No. 9,278,096.
• Amneal’s Paragraph IV filing challenged the patent protection supporting the branded product.
• The case ended through settlement-related dismissal without a reported trial judgment.
• The public disposition does not establish that the patent was valid, infringed or enforceable.
• The case involved generic risk, not biosimilar risk.
• Exact generic launch rights depend on the settlement terms, FDA approval status and the current Orange Book record.

FAQs About Lundbeck v. Amneal and Trintellix Patent Litigation

What was Amneal trying to launch?

Amneal sought FDA approval for generic vortioxetine hydrobromide tablets corresponding to Trintellix.

Was the ’096 patent invalidated in the Amneal case?

No reported merits decision in the Amneal action invalidated the ’096 patent.

Did Lundbeck obtain an injunction against Amneal?

The public disposition does not establish a permanent injunction entered after trial. The case ended without a reported merits judgment.

Is vortioxetine subject to biosimilar competition?

No. Vortioxetine is a small-molecule antidepressant regulated through the ANDA generic-drug pathway.

Does the case determine when Amneal could launch?

No. The docket disposition alone does not establish Amneal’s launch date. Any launch right would depend on the parties’ settlement, FDA approval and surviving patent restrictions.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
2. United States Patent and Trademark Office. (2024). Patent Center and patent term information for U.S. Patent Nos. 7,144,884 and 9,278,096.
3. U.S. Food and Drug Administration. (2016). FDA approves name change for Brintellix to Trintellix.
4. U.S. District Court for the District of Delaware. (2018). H. Lundbeck A/S v. Amneal Pharmaceuticals LLC, No. 1:18-cv-00175-RGA. Public docket record.
5. United States Code. (2024). 21 U.S.C. § 355 and 35 U.S.C. § 271(e)(2).